Invention Grant
- Patent Title: Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
-
Application No.: US17286437Application Date: 2020-08-12
-
Publication No.: US11261259B2Publication Date: 2022-03-01
- Inventor: Wenqing Jiang , Lei Fang , Zhengyi Wang , Bingshi Guo , Eunyoung Park , Eunsil Sung , Byungje Sung
- Applicant: I-Mab Biopharma US Limited , ABL Bio Inc.
- Applicant Address: US MD Gaithersburg; KR Seongnam-Si
- Assignee: I-Mab Biopharma US Limited,ABL Bio Inc.
- Current Assignee: I-Mab Biopharma US Limited,ABL Bio Inc.
- Current Assignee Address: US MD Gaithersburg; KR Seongnam-Si
- Agency: Sheppard Mullin Richter & Hampton LLP
- Agent Alex Nie
- Priority: WOPCT/CN2019/100162 20190812,WOPCT/CN2019/104508 20190905,WOPCT/CN2020/071954 20200114,WOPCT/CN2020/087968 20200430
- International Application: PCT/CN2020/108707 WO 20200812
- International Announcement: WO2021/027850 WO 20210218
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; A61K39/00
Abstract:
Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.
Public/Granted literature
- US20210317224A1 ANTI-CLAUDIN 18.2 AND ANTI-4-IBB BISPECIFIC ANTIBODIES AND USES THEREOF Public/Granted day:2021-10-14
Information query
